

Retinae



Helps in primary retinal diseases by slowing retinal degeneration and in secondary retinal conditions caused by systemic diseases such as diabetes (1, 2, 3, 4, 5).

- + **Lutein and Zeaxanthin:** Protect the retina against age-related retinal degeneration (1, 2, 3, 4, 5).
- + **Minerals (Zn, Cu):** Essential for eye development; help slow visual acuity loss (2, 6, 7).
- + **Vitamins (C, E):** Antioxidants; help slow visual acuity loss (7).

- + **Lactoferrin:** Antimicrobial, antifungal, anti-inflammatory and anticancer properties (16).
- + **Omega-3 fatty acids:** Cytoprotective and antioxidant effects; prevents neovascularization (4, 8, 13, 14, 15).
- + **Vitamins (B6, B9, B12):** Reduce homocysteine levels, a risk factor for the development of retinal degeneration (9, 10, 11).

COMPOSITION

COMPOSITION PER TABLET (750mg): Omega-3 fatty acids (400mg), Marigold flower (*Tagetes sp.*) (source of lutein, 4mg; and zeaxanthin, 0.8mg), Lactoferrin (5mg), Dicalcium phosphate (213,19mg), Magnesium stearate (10mg).

ADDITIVES PER TABLET (750mg):

Flavouring agents: Chicken flavouring.

Vitamins: Vitamin C, Vitamin E, Niacinamide, Calcium D-pantothenate, Vitamin B6, Vitamin B2, Biotin, Vitamin B12, Vitamin B1, Folic acid.

Trace elements: Zinc (Zinc oxide) (4mg), Manganese (Manganese sulphate monohydrate) (0.8mg), Selenium (Sodium selenite) (22µg), Copper (Copper(II) sulphate pentahydrate) (0,4mg).

Emulsifier: Microcrystalline cellulose (E 460).

INSTRUCTIONS FOR USE

Oral administration, once daily, with one of the main meals.

- Pets under 5kg: ½ tablet
- Pets from 5 to 10kg: 1 tablet
- Pets from 10 to 20kg: 1½ tablets
- Pets from 20 to 40kg: 2 tablets
- Pets over 40kg: 2½ tablets

STORAGE CONDITIONS

Store in a cool and dry place, protected from light.

PRESENTATION

Solid form: 30 tablets.



Take care of your pet

BÖHMEN PHARMA LABORATORIES
Av. De la Llana 123 | 08191 Rubí (Barcelona) - Spain
E-mail: drvet@groupandersen.com

REFERENCES

- (1) Association between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in age-related macular degeneration study (CAREDS): ancillary study of the women health initiative. Moeller SM, Parekh N, Tinker L et al. CAREDS researchh study group. Arch Ophthalmol 2006; 124:1151-1162.
- (2) Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye study. Tan JX, Wang JJ, Flood V, et al. Ophthalmology 2006; 115:334-341.
- (3) Plasma lutein and zeaxanthin and other carotenoids as modifiable risk for age-related maculopathy and cataract: Delcourt C, Camiere I, Delage M et al. POLA study group. The POLA study. Invest Ophthalmol Vis Sci 2006; 47:2329-2335.
- (4) Age-Related Eye Disease Study 2. Manual of procedures 2009; http://www.web.emms.com/study/areds2/resources/areds2_map.pdf.
- (5) Lutein in patients with cataracts and age related macular degeneration: a long term supplementation study. Ormedlia B, Granada F, Bianco I, Vaquero M, Calfalà C. J Sci Food Agric; 01:904-909.
- (6) Zinc in the eye. Karcioglu A7. Surv Ophthalmol 1982; 27:114-122.
- (7) Age-Related Eye Disease study research group. A randomized, placebo controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 2001; 119:1417-1436.
- (8) The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. San Giovanni JP, Chew EY. Prog Retino Eye Res 2005; 24:87-138.

- (9) Homocysteine, vitamin B12, and folic acid in age-related macular degeneration. Nowak M, Swiatkowska E, Wlaskzynski T, et al. Eur J Ophthalmol 2005; 15:764-767.
- (10) Plasma homocysteine and total thiol content in patients with exudative age-related macular degeneration. Corak K, Roman R, Roth S, et al. Eye 2006; 20:203-207.
- (11) Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women Christen WG, Glynn RJ, Chew EY, et al. Arch Intern Med 2009; 169:335.
- (12) Do age-related macular degeneration and cardiovascular disease share common antecedents? Snow KK, Seddon JM. Ophthalmol Epidemiol 1999; 6:125-143.
- (13) Docosahexaenoic acid enhances the antioxidant response of human fibroblasts by upregulating α -glutamyl-cystinyl ligase and glutathione reductase. Arab K et al. Br J Nutrition 2006; 95:18-26.
- (14) Docosahexaenoic Acid Improves Endogen Antioxidant Defense in Arpe-19 Cells - Gasso F, Domingo JC et al. ARVO 2008; Poster 5932/A06.
- (15) Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with macular age-related macular degeneration. Augood C, Chakravarty I, Young I, et al. Am J Clin Nutr 2008.
- (16) Multifunctional Iron Bound Lactoferrin and Nanomedical Approaches to Enhance Its Bioactive Functions. Jaggi R, Kanwar, Kislay Roy, Yogesh Patel, Shu-Feng Zhou, Manju Rawal Singh, Deependra Singh, Muhammad Nisar, Rakish Sehgal, Akh Sehgal, Rom Sarup, Singh, Sanjay Garg and Rupinder K. Kanwar. Molecules 2015, 20, 9703-9731.